

An experimental and theoretical study on the regioselectivity of successive bromination sites of 7,8-dimethyl-2,4-diphenyl-3*H*-1,5-benzodiazepine. Efficient microwave assisted solventless synthesis of 4-phenyl-3*H*-1,5-benzodiazepines

Constantinos A. Tsoleridis,^{1*} Minodora Pozarentzi,¹ Sophia Mitkidou,² and Julia Stephanidou-Stephanatou¹

¹ *Laboratory of Organic Chemistry, Aristotle University of Thessaloniki, Thessaloniki, 54124, Macedonia, Greece*

² *Department of Science, School of Technological Applications, Technological Institute of Kavala, Kavala, Greece*

E-mail: tsolerid@chem.auth.gr

Abstract

A facile synthesis of 4-phenyl-1*H*-1,5-benzodiazepines from *o*-phenylenediamines and 1,3-diketones in the presence of a catalytic amount of acetic acid has been achieved, in excellent yields, under microwave irradiation. This method is very simple and the reaction conditions are mild, environmentally friendly and more important, quick. Moreover, the complete assignment of ¹H- and ¹³C-NMR signals was achieved using 1D and 2D experiments in conjunction with DFT/GIAO calculated isotropic magnetic shieldings at the B3LYP density functional level. The geometries of selected compounds were optimized using the 6-31G(d) basis set, whereas the nuclear shielding constants were calculated using the 6-311G(d) basis set. The theoretical values were found very close to the experimental data. In addition, the allylic versus benzylic bromination as well as the regioselectivity of the successive bromination sites was studied on 7,8-dimethyl-2,4-diphenyl-1*H*-1,5-benzodiazepine, whereupon the enhanced reactivity of the 3-CH₂ group was established. Semiempirical (AM1, PM3) and DFT calculations confirmed that the free radical bromination selectivity of the above benzodiazepine is related to the stability of the intermediate radicals formed during the bromination process. In addition, the inversion energy of H₂C(3) group was calculated by AM1 or PM3 using the reaction path method and was found to be ~8.6 or ~9.0 kcal/mol, respectively, very close to the experimental value of *ca.* 12.4 kcal/mol.

Keywords: Allylic/benzylic bromination, 1,5-benzodiazepines, DFT GIAO calculations, inversion energy, microwave synthesis, regioselectivity

Introduction


Benzodiazepines have recently received a lot of attention because of their wide range of therapeutic and pharmacological properties. Many members of the diazepine family are nowadays widely used as anti-anxiety, antidepressant, sedative, hypnotic, anticonvulsant, analgesic and anti-inflammatory agents.¹⁻³ Benzodiazepine derivatives also find commercial use as dyes for acrylic fibers.⁴ In addition, 1,5-benzodiazepines are important intermediates for the synthesis of various fused ring heterocyclic compounds such as oxazino-, oxadiazolo-, furano- and triazolo-benzodiazepines.⁵ Due to their wide range of biological, industrial and synthetic applications, the development of mild, efficient and environmentally friendly protocols continues to be a challenging endeavour in synthetic organic chemistry. As a result, various methods concerning the synthesis of 2,3-dihydro-1*H*-1,5-benzodiazepines appeared recently in the literature.⁶⁻⁷ To the contrary, the synthesis of 3*H*-1,5-benzodiazepines has received little attention and only a few methods are reported in the literature for their preparation.⁸⁻⁹ Moreover, bromo substituted derivatives continue to be very important synthetic intermediates for pharmaceutical and other chemical related industries and the issue of allylic over benzylic or aromatic ring bromination is still very challenging. So, in this article as a part of a more extensive study on the chemistry of benzodiazepines we wish to report an efficient and rapid synthesis of 3*H*-1,5-benzodiazepines under “green chemistry” conditions (microwave irradiation without solvent) and a study of their allylic versus benzylic bromination as well as the regioselectivity of their successive bromination sites.

Results and Discussion

This synthesis was carried out simply by mixing *o*-phenylenediamines **1** with 1,3-diketones **2** (in a 1.5:1 molar ratio) in the presence of a catalytic amount of acetic acid and irradiating in a Milestone Ethos 1600 microwave oven (Scheme 1), whereupon the benzodiazepine derivatives **3** were obtained in almost quantitative yield (Table 1). However, from the reaction of the 3-methyl substituted diketone **2b** with diamine **1b** the benzimidazole **4** was also isolated in 20% yield. The reaction between diamine **1a** and diketone **2c** was also repeated at room temperature for 24 h, whereupon benzodiazepine **3b** was isolated in only 46% yield. It should be mentioned that the 2,4-diphenyl-3*H*-1,5-benzodiazepine **3b** has been prepared by standard methods in comparatively low yield (~40–45%),^{9a} whereas the synthesis of the 7,8-dimethyl derivative **3d** has been reported previously from 4,5-dimethyl-1,2-phenylenediamine and diphenylpropynone in low yield (21%).¹⁰

In order to study the bromination selectivity (benzylic and/or allylic), the brominations were performed on the 7,8-dimethyl derivative **3d** with NBS under reflux in carbon tetrachloride solution using a 200 W light bulb resulting in the brominated derivatives **5–10** (Scheme 2). In contrast, the use of NBS in the presence of benzoylperoxide or 2,2'-azobisisobutyronitrile

(AIBN) was unsuccessful, due to the formation of many products.



a R¹=R²=H

b R¹=R²=CH₃

a R³=CH₃, R⁴=H

b R³=R⁴=CH₃

c R³=Ph, R⁴=H

a R¹=R²=R⁴=H, R³=CH₃

b R¹=R²=R⁴=H, R³=Ph

c R¹=R²=R³=CH₃, R⁴=H


d R¹=R²=CH₃, R³=Ph, R⁴=H

e R¹=R²=R⁴=CH₃, R³=Ph

(^a) MW, acetic acid (cat. amount)

1:2 = 1.5:1

(^b) In the case of reaction of **1b** with **2b**
compound **4** was also obtained



Scheme 1. Synthesis of 3*H*-1,5-benzodiazepines **3**.


Table 1. Preparation of 4-phenyl-3*H*-1,5-benzodiazepines **3** using microwaves

Reactants	Product 3	Milestone microwave oven		
		Power (W)	Time (min)	Yield %
1a + 2a	3a	150	3	93
1a + 2c	3b	250	10	95
1b + 2a	3c	150	3	96
1b + 2c	3d	250	8	97
1b + 2b	3e	200	2	62 ^a

^a Benzimidazole **4** was also isolated in 20% yield.

Reaction of **3d** with 1.1 equiv. of NBS revealed that allylic bromination was the favored initial reaction site. After the first 5 min. TLC of the reaction mixture showed the presence of compound **5** and unreacted **3d**. After 30 min compound **3d** was consumed and two spots appeared on the TLC plate, corresponding to a mixture of the 3-bromo derivative **5** (20%) and the 3-bromo-7-bromomethyl derivative **6** (45%). Reaction with 2.2 equiv. of NBS resulted in **6** (52%) and the tribromo derivative **7** (24%). Subsequent reaction with 3.3 equiv. of NBS gave compound **7** (46%) and the tetrabromo derivative **8** (26%) and reaction with 4.4 equiv. of NBS

gave compound **8** (50%) and the pentabromo derivative **9** (23%). However, with 6 equiv. of NBS the pentabromo derivative **9** was regioselectively formed in excellent yield (95%). It should also be noted that the brominated compounds **6–9** were formed with a satisfactory degree of regioselectivity (~2:1), in almost all cases favoring the less brominated derivatives. Finally, by using even larger amounts of NBS (7 equivalents or more) and longer reaction times (≥ 4 h) a small amount of the hexabromo derivative **10** was additionally obtained in 14% yield.



Scheme 2. Bromination products of 7,8-dimethyl-2,4-diphenyl-3H-1,5-benzodiazepine (**3d**).

From this study it can be concluded that the $\text{H}_2\text{C}(3)$ allylic group appears to be more reactive than the 7- or 8-methyl groups towards bromination under radical conditions. However, dibromination on the $\text{BrHC}(3)$ group was not observed, but subsequent bromination occurs preferentially on the benzylic positions. Monobromination of the $\text{H}_2\text{C}(3)$ group of the benzodiazepine **3b** occurs also with NBS without the use of light or benzoylperoxide.^{9b} Nevertheless, dibromination in the 3 position of benzodiazepine **3d** was possible by using the

KBrO₃/NaHSO₃ reagent. In a typical experiment,¹¹ to a two-phase system comprised of ethyl acetate involving **3d** and aqueous KBrO₃ (3 equiv.), an aqueous solution of NaHSO₃ (3 equiv.) was added and the mixture was allowed to react at room temperature for 4 h, whereupon the 3,3-dibromo derivative **11** was isolated as the main reaction product in 56% yield along with the 3-bromobenzodiazepine **5** in 23% yield (Scheme 2).




Figure 1. COLOC correlations observed for compounds **3c**, **3d**, **6**, **9** and **10**.

Structure assignment by NMR spectra investigations

The structural assignments of the compounds studied were established by analysis of their NMR spectra (¹H, ¹³C, DEPT, COSY H–H, NOESY H–H, HETCOR C–H, and COLOC C–H). In

Figure 1 the long range C–H correlations (COLOC) used for the structural assignments of compounds **3c**, **3d**, **6**, **9** and **10** are depicted.

Concerning the NMR study of benzodiazepines **3**, due to the slow inversion of the diazepine cycloheptatriene ring at ambient temperature, the 3-methylene protons give a very broad, hardly distinguished, $^1\text{H-NMR}$ signal at $\delta \sim 3.5\text{--}4.0$. At very low temperatures, where the inversion practically does not occur, the signal of each proton is differentiated.¹² The signal at $\delta \sim 2.5$ can be assigned to the proton in the *endo* site of the diazepine ring, where it is shielded by both C=N anisotropy cones (+).




Figure 2. Molecular models (AM1) of: (a) Compound **3d** with endo-exo configuration of cycloheptatriene methylene protons; (b) 3-Bromo derivative **5** with endo configuration of Br.




Figure 3. Variation of the relative energy of formation ($\Delta\Delta H_f$) versus the dihedral angle between Br–CH–C(8)–C(7) as the group **Br₂HC–C(8)** is rotating: (a) In compound **9** and (b) in compound **10** (AM1).

On the other hand, the *exo* proton being closer to the deshielding cones of the two phenyls and of the two C=N bonds resonates at much lower field ($\delta \sim 5.0$) (Fig. 2a). In the case of compound **3e**, the 3-methyl group prefers, in order to diminish the repulsive interactions, the *endo* conformation, so the methyl protons show a doublet at $\delta = 0.85$ ($J = 7.15$ Hz), whereas the 3-methine proton gives a quartet at $\delta = 5.56$ ($J = 7.15$ Hz). The BrHC(3) methine protons of all compounds **5–10** being under the influence of the two phenyls, the two N=C bonds, and additionally of the bromine atom (Fig. 2b) resonate at $\delta \sim 7.0$. In compound **9** the Br₂CH– groups are rotating relative to each other slowly at the NMR time scale, like two gear wheels, resulting to the very broad C(6/9) and C(7/8) carbon signals. Similar broadening is observed for the HC(6/9) and the Br₂HC–C(7/8) proton signals. As a result of the above broadening, COLOC correlations could not be observed for the carbons C(6/9) and C(7/8) of compound **9**. For the same reason, COLOC correlations could not be observed for the H₂C(3) protons of compounds **3a–3d** (Fig. 1).

An AM1 simulation of the rotation of Br₂HC–C(8) group at 298 K gave a sinusoid like curve for the variation of the relative energy of formation (ΔH_f) versus the dihedral angle between the atoms in group Br–C–C(8)–C(7) with two energy barriers of ~ 9.3 kcal for a full rotation (Fig. 3a). In compound **10** the –CBr₃ group is more sterically hindering than the CHBr₂ group in **9** and the AM1 approximation of the rotation of the two substituted methyls at C(7/8) gave a more complicated sinusoid like line with two energy barriers of ~ 13.2 kcal for a full rotation (Fig. 3b). As a result, the rotation of both groups is prohibited and the NMR signals for carbon and proton atoms in compound **10** are of normal width.

For comparison reasons in Table S1 (see Supporting Information) the chemical shifts for ¹³C-NMR spectra of all synthesized compounds are summarized. From this table it can be concluded that only small differences have been observed for similar atoms, especially in the case of bromides **5–10**, formed by the stepwise bromination. In order to clear up the ambiguity for the assignment of the chemical shifts, in the cases with non-identical substituents at C(2/4) or at CH₃–C(7/8), the isotropic magnetic shieldings for the atoms in question have been calculated^{13,14} by the DFT/GIAO method and their relative values to TMS, Δ_{IMS} , are presented in Table 2. From the comparison of experimental and calculated chemical shifts a good coincidence for the trend of the change of chemical shifts for different substituents in positions 2/4 and 7/8 is found. Once the chemical shifts of C(2)/C(4), C(5a)/C(9a) and C(1')/C(1'') pairs have been established, it was possible to distinguish and assign the rest of chemical shifts using COLOC correlations (Fig. 1). In the cases where the ¹³C chemical shift differences are very small or the ¹H chemical shifts are overlapping the ambiguity in assignment, although meaningless, still remains.

Theoretical study on bromination

The molecular model of benzodiazepine **3d** was investigated by semiempirical MO calculations (AM1 and PM3 models) (Fig. 2a). The inversion energy of the H₂C(3) group determined experimentally by variable temperature ¹H-NMR measurements on related compounds gave ΔG^* values of *ca.* 12.4 kcal/mol.¹² The same inversion energy calculated by AM1 or PM3 using the

reaction path method was found to be ~8.6 or ~9.0 kcal/mol, respectively, very close to the experimental value.

The molecular model of the 3-bromo derivative **5** is depicted in Figure 2b as the **5-endo** conformer. In the case of **5-exo** derivative the Van der Waals interactions would be stronger, therefore the bromine takes preferentially the *endo* configuration with the energy difference being $\Delta\Delta H_f = 6.47/4.29$ kcal/mol (AM1/PM3). The inversion energy of BrHC(3) group is calculated to be ~14.1/~10.6 kcal/mol (AM1/PM3).

N-Bromosuccinimide (NBS) has been used quite extensively, especially for allylic and benzylic brominations. The authors anticipate that under the reaction conditions (reflux in CCl₄, light and/or radical initiators) bromine and bromine radicals are produced in low concentration and that the rate determining step for benzylic bromination is the hydrogen abstraction.¹⁵ The ease of hydrogen abstraction and the stability of the resulting radical can override other factors, such as steric effects leading to the selectivity of radical formation and subsequently to the bromination product. Hence, in the present study the stability of the successive radicals was studied.

Table 2. Isotropic magnetic shieldings relative to TMS^a (Δ IMS) in conjunction with the chemical shifts for some carbon and proton nuclei of selected compounds.

a) Benzodiazepines **3a–3d**

Atom	3a		3b		3c		3d	
	Δ IMS ^b	ppm	Δ IMS	ppm	Δ IMS	ppm	Δ IMS	ppm
2	158.57	157.9	155.53	154.1	157.22	156.4	152.52	153.0
4	152.50	153.3	155.53	154.1	150.85	151.9	152.52	153.0
5a	146.35	140.2	147.15	140.7	144.78	138.5	145.62	138.8
6	134.60	127.6	135.22	128.7	135.05	128.7	135.78	129.1
7	129.01	125.2	129.54	125.4	140.35	133.8	141.24	134.6
8	129.21	125.0	129.54	125.4	140.67	134.1	141.24	134.6
9	134.22	128.4	135.22	128.7	134.84	128.0	135.78	129.1
9a	147.21	140.6	147.15	140.7	145.54	138.2	145.62	138.8
1'	142.42	137.0	144.02	137.2	142.43	137.1	142.33	137.5
1''	28.68	27.00	144.02	137.2	28.63	26.8	142.33	137.5
H-C(6)	7.62	7.54	7.68	7.61	7.43	7.31	7.52	7.38
H-C(9)	7.54	7.45	7.68	7.61	7.32	7.22	7.52	7.38


b) Brominated Benzodiazepines 5–8

Atom	5		6		7		8	
	Δ IMS	ppm	Δ IMS	ppm	Δ IMS	ppm	Δ IMS	ppm
2	137.32	149.4	156.89	151.2	157.30	151.9	158.30	152.9
4	137.32	149.4	156.36	150.6	157.58	151.9	157.71	152.5
5a	127.57	139.1	145.62	139.1	147.68	141.1	146.62	141.50
6	120.76	129.5	139.10	130.5	139.54	131.5	137.69	131.3
7	124.39	136.6	142.77	135.1	144.25	135.1	144.15	131.1
8	124.39	136.6	145.23	136.4	144.08	135.1	136.66	130.7
9	120.76	129.5	138.06	130.7	139.13	131.5	136.07	130.7
9a	127.57	139.1	146.23	141.2	147.47	141.1	148.16	141.55
1'	127.18	137.4	146.12	137.2	145.51	136.7	145.21	136.5
1''	127.18	137.4	145.29	127.9	145.18	136.7	144.97	136.6
H–C(6)	7.39	7.49	7.72	7.67	7.70	7.70	8.44	8.26
H–C(9)	7.39	7.49	7.58	7.52	7.65	7.70	8.00	7.62

^a Isotropic magnetic shielding for TMS calculated by B3LYP/6-31G(d)//B3LYP/6-311G(d) method: For ¹H IMS_{TMS} = 32.20; for ¹³C IMS_{TMS} = 183.60 ppm. ^b Relative Δ IMS = IMS_{TMS} – IMS_X for magnetic nuclei X.

Since CCl₄ is a neutral non-polar solvent, the calculation of geometries and thermodynamic quantities of the species in vacuum resembles that of the low concentration solution conditions, where solvent effects are negligible.

Among the methods, semiempirical calculations give rapid results, although they are considered not to be quantitatively accurate. As long as relative energies are compared the possible errors of calculations may be ignored.



Scheme 3. Possible intermediate radicals formed during the bromination of benzodiazepine **3d**.

Table 3. Calculated heats of formation ΔH_f (AM1 and PM3) and total energies (UB3LYP/ 6-31G(d)) of possible radical intermediates as well with their relative stabilities ($\Delta\Delta H_f$).

AM1	UHF			PM3	UHF				
Calcd ΔH_f (kcal/mol)				$\Delta\Delta H_f$	Calcd ΔH_f (kcal/mol)		$\Delta\Delta H_f^a$		
5a	131.56	5b	132.09	0.53	5a	114.01	5b	119.06	5.05
6a	140.54	11b	140.76	0.22 ^{b)}	6a	126.56	11b	124.84	-1.72 ^{b)}
7a	146.31	7b	142.51	-3.80	7a	133.41	7b	135.10	1.69
8a	148.76	8b	152.13	3.37	8a	144.66	8b	140.76	-3.90
9a	159.01	9b	156.85	-2.16	9a	151.56	9b	153.41	1.85
DFT	E_{total}^c				E_{total}^c			ΔE^d	
5a	-997.370040			5b	-997.357762			7.71	
6a	-3568.457390			11b	-3568.461932			-2.85 ^{b)}	
7a	-6139.560250			7b	-6139.563327			-1.93	
8a	-8710.666361			8b	-8710.664697			1.04	
9a	-11281.760882			9b	-11281.754440			4.04	

^a $\Delta\Delta H_f$ is the difference between the heat of formation of isomers **b** and **a** (kcal/mol). ^b For **11b**–**6a**. ^c In Hartrees, 1 Hartree=627.51 kcal/mol. ^d Difference in E_{total} between the isomers **b** and **a** (kcal/mol)

On the other hand, high level *ab initio* calculations are much more computational demanding but could give accurate quantitative results. In the present study, we have used the AM1 and PM3 models in order to compare them, but also to compare with the experimental results. Moreover, DFT calculations (UB3LYP/6-31G(d)) constitute an excellent compromise between computational cost and accurate energetic results. Therefore, DFT calculations have been carried out in order to use these results as reference. In Scheme 3 some possible intermediate radicals formed during the bromination process of benzodiazepine **3d** are depicted. The radicals labeled with **a** lead to the products obtained experimentally, whereas those labeled with **b** are considered imaginary. All calculated results are shown in Table 3.

Between the radicals **5a** and **5b**, which could be formed initially, **5a** is calculated to be more stable by all methods, probably due to the extra stabilization gained by the two C(Ph)=N groups. In addition, the 3-*endo* hydrogen is in a favored position to be abstracted easily. After the first bromine substitution, the second radical can be formed either in the 3 position (**11a**) or in the H₃C(7/8) group (**6a**). Radical **11a** is calculated to be more stable than **6a**, but the abstraction of the second methylene hydrogen to yield **11a** is hindered, since the proximity of the bromine radical must overcome the increased Van der Waals repulsive forces, due to the bromine already present and the two phenyls at the 2- and 4-positions. This hydrogen can be abstracted only after the inversion of the BrHC(3) group, a process being hindered, as noted above. On the other hand, there are two symmetrically located methyls that can react freely with the proton abstracting radical. For the additional brominations, the stability difference between **7a** and **7b** radicals only in the case of PM3 calculation favors **7a** and even in this case the energy difference is small. Concerning the relative stability of the radicals **8a** and **8b**, only the PM3 method gives results favoring radical **8b**. For radicals **9a** and **9b** both DFT and PM3 calculations give priority to radical **9a**. The small energy differences between the successive bromination products justify the isolation of product mixtures differing by one bromine atom. The absence of brominated products on both phenyl rings and on the condensed aromatic can be attributed to the combined electron withdrawing effect of the C(Ph)=N groups. To the contrary, in the case of 1*H*-1,5-benzodiazepines, the bromination under the same experimental conditions on the condensed aromatic ring is the predominant one.¹⁶ Finally, in the case of bromination with KBrO₃/NaHSO₃ in a dual polar solvent (H₂O/AcOEt) the reaction follows a polar mechanism of electrophilic substitution that first leads to monobromination on the H₂C(3) allylic position followed by the second substitution on the same carbon, because of the strong deactivation of the other sites of the molecule.

In conclusion, a facile, quick and environmentally friendly synthesis of 4-phenyl-3*H*-1,5-benzodiazepines under microwave irradiation using a catalytic amount of acetic acid has been achieved in excellent yield. In addition, from the theoretical study of the free radical bromination selectivity, it can be concluded that prediction of the bromination products is in accordance with the experimental results. The PM3 method predicts the stability of the intermediate radicals better than AM1 and in almost all cases is as good as DFT. A full assignment of ¹H- and ¹³C-NMR chemical shifts of all studied compounds has also been achieved and a very good

approximation of chemical shifts was calculated by the B3LYP/6-31G(d)//B3LYP/6-311G(d) method. In addition, the inversion energy of the H₂C(3) group was calculated by AM1 or PM3 using the reaction path method and was found to be ~8.6 or ~9.0 kcal/mol, respectively, very close to the experimental value of *ca.* 12.4 kcal/mol.

Experimental Section

General Procedures. Melting points were measured with a Kofler hot-stage apparatus and are uncorrected. Column chromatography was performed on 230-400 mesh silica gel (Merck) and preparative TLC plates with silica gel 60 F₂₅₄ (Merck) were used. A mixture of petroleum ether/AcOEt, (20:1) was used as eluent for all chromatographic separations. Petroleum ether refers to the fraction boiling between 60 and 80 °C. IR spectra were recorded as thin films or KBr pellets either on a Perkin-Elmer 297 or on a Perkin-Elmer 1650 FT-IR spectrometer and are reported in wave numbers (cm⁻¹). NMR spectra were recorded at room temperature on a Bruker AM 300 spectrometer at 300 MHz for ¹H and 75 MHz for ¹³C, respectively, using CDCl₃ as solvent. Chemical shifts are expressed in δ values (ppm) relative to TMS as internal standard for ¹H and relative to TMS (0.00 ppm) or to CDCl₃ (77.05 ppm) for ¹³C-NMR spectra. Coupling constants ⁿJ values are reported in Hz. Low resolution electron impact mass spectra (EIMS) were obtained on a VG TS-250 instrument and are reported in *m/z* (rel. int. %). Elemental analyses were performed on a Perkin-Elmer 2400-II CHN analyzer. Structural assignments of the derived compounds were established by analysis of their combined spectroscopic data.

Theoretical calculations. The minimum energy conformation of each compound was computed with the AM1 and PM3 methods as implemented in the MOPAC package¹⁷ and referred to vacuum. All geometry optimizations were carried out without symmetry constraints and stationary points were refined by minimization of the gradient norm of the energy to at least 0.01 kcal/mol, using the LET and PRECISE keywords. The heats of formation (ΔH_f) for radicals were calculated by the unrestricted (UHF) wave function using the keyword LET. The DFT geometry optimizations and total energy calculations of the radicals have been performed with the standard 6-31G(d) basis set by using the unrestricted B3LYP functional¹⁸ as implemented in the Gaussian 2003 package.¹⁹ Moreover, the complete assignment of ¹H- and ¹³C-NMR signals was possible using 1D and 2D experiments in conjunction with DFT/GIAO calculated isotropic magnetic shielding^{13,14} at the B3LYP density functional level. The geometries of selected compounds have been optimized using the 6-31G(d) basis set, whereas the isotropic nuclear magnetic shielding constants (IMS) were calculated by using 6-311G(d) basis set and the results are presented as the differences Δ IMS relatively to TMS shielding calculated at the same level of theory. The calculated values are very close to the experimental data.

Synthesis of 4-phenyl-3*H*-1,5-benzodiazepines (**3**) under microwave irradiation. General procedure

The 1,3-dicarbonyl compound **2** (1.0 mmol), 1,2-phenylenediamine derivative **1** (1.5 mmol) and a trace of acetic acid were mixed thoroughly and were irradiated in a Milestone Ethos 1600 microwave oven at a power and time indicated in Table 1. The diazepine **3** was isolated from the reaction mixture by column chromatography.

2-Methyl-4-phenyl-3*H*-1,5-benzodiazepine (3a). 93% Yield, mp 87–88 °C (lit.²⁰ mp 88 °C). ¹H NMR δ ppm: 2.30 (3H, s, CH₃-2), 3.3 (2H, br s, 3), 7.23–7.31 (2H, m, 7,8), 7.40–7.50 (3H, m, 3',4',5'), 7.42–7.48 (1H, m, 9), 7.51–7.57 (1H, m, 6), 8.01–8.07 (2H, m, 2',6'). ¹³C NMR δ ppm: 27.0 (CH₃-2), 38.5 (3), 125.0 (8), 125.2 (7), 127.6 (6), 128.1 (2',6'), 128.4 (9), 128.7 (3',5'), 130.7 (4'), 137.0 (1'), 140.2 (5a), 140.6 (9a), 153.3 (4), 157.9 (2). EIMS: *m/z* (%) 234 (M⁺, 63), 219 (30), 132 (51), 103 (62).

2,4-Diphenyl-3*H*-1,5-benzodiazepine (3b). 95% Yield, mp 138–140 °C (ethanol) (lit.^{9a} mp 137.5–139 °C). ¹H NMR δ ppm: 3.2 (2H, br s, 3), 7.34 (2H, ddd, *J* = 7.7, 6.0, 2.0 Hz, 7,8), 7.36–7.47 (6H, m, 3',4',5',3'',4'',5''), 7.61 (2H, ddd, *J* = 7.7, 6.0, 2.0 Hz, 6,9), 7.93–8.00 (4H, m, 2',6',2'',6''). ¹³C NMR δ ppm: 34.8 (3), 125.4 (7,8), 128.1 (2',6',2'',6''), 128.6 (3',5',3'',5''), 128.7 (6,9), 130.5 (4',4''), 137.2 (1',1''), 140.7 (5a,9a), 154.1 (2,4). EIMS: *m/z* (%) 296 (M⁺, 100), 219 (21), 194 (37), 165 (15), 103 (67).

2,7,8-Trimethyl-4-phenyl-3*H*-1,5-benzodiazepine (3c). 96% Yield, mp 116–118 °C (lit.¹⁰ mp 115–117 °C). ¹H NMR δ ppm: 2.26 (3H, s, CH₃-2), 2.31 (6H, s, CH₃-7, CH₃-8), 3.2 (2H, br s, 3), 7.22 (1H, s, 9), 7.31 (1H, s, 6), 7.41–7.45 (3H, m, 3',4',5'), 7.99–8.03 (2H, m, 2',6'). ¹³C NMR δ ppm: 19.25 (CH₃-7), 19.33 (CH₃-8), 26.8 (CH₃-2), 38.3 (3), 127.9 (2',6'), 128.0 (9), 128.6 (3',5'), 128.7 (6), 130.3 (4'), 133.8 (7), 134.1 (8), 137.1 (1'), 138.2 (9a), 138.5 (5a), 151.9 (4), 156.4 (2). EIMS: *m/z* (%) 262 (M⁺, 100), 248 (30), 220 (15), 160 (14).

7,8-Dimethyl-2,4-diphenyl-3*H*-1,5-benzodiazepine (3d). White needles (97%), mp 167–168 °C (ethanol) (lit.¹⁰ mp 163–164 °C). ¹H NMR δ ppm: 2.36 (6H, s, CH₃-7, CH₃-8), 3.3 (2H, br s, 3), 7.36–7.41 (6H, m, 3',4',5',3'',4'',5''), 7.38 (2H, s, 6,9), 7.93–7.96 (4H, m, 2',6',2'',6''). ¹³C NMR δ ppm: 19.5 (CH₃-7, CH₃-8), 34.9 (3), 128.1 (2',6',2'',6''), 128.7 (3',5',3'',5''), 129.1 (6,9), 130.4 (4',4''), 134.6 (7,8), 137.5 (1',1''), 138.8 (5a,9a), 153.0 (2,4). EIMS: *m/z* (%) 324 (M⁺, 100), 247 (15), 222 (35), 207 (20), 103 (47).

3,7,8-Trimethyl-2,4-diphenyl-3*H*-1,5-benzodiazepine (3e). 62% Yield, oil. ¹H NMR δ ppm: 0.85 (3H, d, *J* = 7.15 Hz, CH₃-3), 2.36 (6H, s, CH₃-7, CH₃-8), 5.56 (q, *J* = 7.15 Hz, 3), 7.36–7.40 (6H, m, 3',4',5',3'',4'',5''), 7.39 (2H, s, 6,9), 7.85–7.90 (4H, m, 2',6',2'',6''). ¹³C NMR δ ppm: 9.4 (CH₃-3), 19.4 (CH₃-7, CH₃-8), 41.8 (3), 127.9 (2',6',2'',6''), 128.6 (3',5',3'',5''), 129.1 (6,9), 130.1 (4',4''), 134.6 (7,8), 137.5 (1',1''), 139.3 (5a,9a), 156.5 (2,4). Anal. Calcd. for C₂₄H₂₂N₂ (338.45): C 85.17; H 6.55; N 8.28. Found: C 85.38; H 6.74; N 8.19.

5,6-Dimethyl-2-phenyl-1*H*-benzimidazole (4). Isolated in 20% yield. Mp 250–252 °C (lit.²¹ mp 251–253 °C). ¹H NMR δ ppm: 2.34 (6H, s, CH₃-5, CH₃-6), 5.1 (1H, br s, NH), 7.35–7.42 (1H, m, 4'), 7.38 (2H, s, 4,7), 7.38–7.46 (2H, m, 3',5'), 8.13–8.17 (2H, m, 2',6'). ¹³C NMR δ ppm: 20.4

(CH₃-5, CH₃-6), 115.3 (br, 4,7), 126.7 (2',6'), 128.8 (3',5'), 129.6 (4'), 130.3 (1'), 131.5 (5,6), 137.9 (br 3a,7a), 151.2 (2).

NBS brominations of compound 3d. General procedure

A magnetically stirred mixture of compound **3d** (0.324 g, 1 mmol) and NBS (0.199 g, 1.1 mmol) in anhydrous CCl₄ (10 mL) was refluxed for 30 min, while irradiating by a 200 W projector light bulb. After cooling at 6°C, the succinimide crystals formed were removed by filtration. The filtrate was evaporated and after column chromatography afforded compounds **5** (0.081 g, 20%) and **6** (0.218 g, 45%).

3-Bromo-7,8-dimethyl-2,4-diphenyl-3H-1,5-benzodiazepine (5). Yellow solid, mp 140–142 °C. ¹H NMR δ ppm: 2.42 (6H, s, CH₃-7, CH₃-8), 6.99 (1H, s, 3), 7.40–7.51 (6H, m, 3',4',5', H-3'',4'',5''), 7.49 (2H, s, 6,9), 7.85–7.90 (4H, m, 2',6',2'',6''). ¹³C NMR δ ppm: 19.7 (CH₃-7, CH₃-8), 35.5 (3), 127.8 (2',6',2'',6''), 129.0 (3',5',3'',5''), 129.5 (6,9), 130.8 (4',4''), 136.6 (7,8), 137.4 (1',1''), 139.1 (5a,9a), 149.4 (2,4). EIMS: *m/z* (%) 402/404 (M⁺, 7), 323 [(M-Br)⁺, 100], 220 (23). Anal. Calcd. for C₂₃H₁₉BrN₂ (403.31): C 68.49; H 4.75; N 6.95. Found: C 68.68; H 4.64; N 6.73.

3-Bromo-7-(bromomethyl)-8-methyl-2,4-diphenyl-3H-1,5-benzodiazepine (6). Mp 188–190 °C. ¹H NMR δ ppm: 2.57 (3H, s, CH₃-8), 4.64 (2H, s, BrCH₂-7), 6.99 (1H, s, 3), 7.45–7.51 (6H, m, 3',4',5',3'',4'',5''), 7.52 (1H, s, 9), 7.67 (1H, s, 6), 7.87–7.92 (4H, m, 2',6',2'',6''). ¹³C NMR δ ppm: 18.7 (CH₃-8), 31.7 (BrCH₂-7), 34.9 (3), 127.8 (2',6'), 127.9 (2'',6''), 129.00 (3',5',3'',5''), 130.5 (6), 130.7 (9), 131.0 (4'), 131.2 (4''), 135.1 (7), 136.4 (8), 137.1 (1'), 137.2 (1''), 139.1 (5a), 141.2 (9a), 150.6 (4), 151.2 (2). EIMS: *m/z* (%) 480/482/484 (M⁺, 72),²² 401/403 [(M-Br)⁺, 61], 322 [(M-2Br)⁺, 41], 103 (100); Anal. Calcd. for C₂₃H₁₈Br₂N₂ (482.21): C 57.29; H 3.76; N 5.81. Found: C 57.15; H 3.80; N 5.73.

When the bromination was repeated with 2.2 equivalents of NBS an inseparable mixture of the dibromo derivative **6** (52% yield) and the tribromo derivative **7** (24% yield) was obtained after purification of the crude reaction mixture on a preparative TLC plate. The yield ratio was calculated from the ¹H-NMR of the mixture.

3-Bromo-7,8-bis(bromomethyl)-2,4-diphenyl-3H-1,5-benzodiazepine (7). ¹H NMR δ ppm: 4.78 (4H, s, BrCH₂-7 and BrCH₂-8), 7.00 (1H, s, 3), 7.42–7.52 (6H, m, 3',4',5',3'',4'',5''), 7.70 (2H, s, 6,9), 7.88–7.95 (4H, m, 2',6',2'',6''). ¹³C NMR δ ppm: 29.7 (BrCH₂-7, BrCH₂-8), 34.5 (3), 127.9 (2',6',2'',6''), 129.0 (3',5',3'',5''), 131.5 (6,9), 131.6 (4',4''), 135.0 (7,8), 136.7 (1',1''), 141.1 (5a,9a), 151.9 (2,4). EIMS: *m/z* (%) 558/560/562/564 (M⁺, 9).²²

When the bromination was repeated with 3.3 equivalents of NBS an inseparable mixture of the tribromo-derivative **7** (46% yield) and the tetrabromo-derivative **8** (26% yield) was obtained after purification of the crude reaction mixture on a preparative TLC plate. The yield ratio was calculated from the ¹H-NMR of the mixture.

3-Bromo-8-(bromomethyl)-7-(dibromomethyl)-2,4-diphenyl-3H-1,5-benzodiazepine (8). ¹H NMR δ ppm: 4.72 (2H, s, BrCH₂-8), 7.00 (1H, s, 3), 7.19 (1H, s, Br₂CH-7), 7.42–7.52 (6H, m, (3',4',5',3'',4'',5''), 7.62 (1H, s, 9), 7.88–7.95 (4H, m, 2',6',2'',6''), 8.26 (1H, s, 6). ¹³C NMR δ

ppm: 28.9 (BrCH₂-8), 34.4 (3), 36.2 (Br₂CH-7), 128.0 and 128.1 (2',6' and 2'',6''), 129.05 and 129.09 (3',5' and 3'',5''), 130.7 (9), 131.1 (8), 131.3 (6), 131.4 and 131.5 (4' and 4''), 136.5 and 136.6 (1' and 1''), 138.5 (7), 141.5 (5a), 141.6 (9a), 152.5 (4), 152.9 (2). EIMS: *m/z* (%) 642/644/646/648/650 (M⁺, 22),²² 322 (29), 103 (49).

When the bromination was repeated with 4.4 equivalents of NBS with reaction time 2 h, an inseparable mixture of the tetrabromo derivative **8** (50% yield) and the pentabromo derivative **9** (23% yield) was obtained after purification of the crude reaction mixture on a preparative TLC plate. The yields were calculated from the ¹H-NMR of the mixture. However, bromination with 6.0 equivalents of NBS and reaction time 2.5 h resulted to the formation of **9** as the only product, obtained in 95% yield after purification of the crude reaction mixture on a preparative TLC plate.

3-Bromo-7,8-bis(dibromomethyl)-2,4-diphenyl-3H-1,5-benzodiazepine (9). Mp 188–189 °C. ¹H NMR δ ppm: 7.00 (1H, s, 3), 7.23 (2H, br s, Br₂CH-7, Br₂CH-8), 7.44–7.52 (m, 3',5',3'',H-5''), 7.47–7.55 (2H, m, 4',4''), 7.90–7.95 (4H, m, 2',6',2'',6''), 8.00 (2H, br s, 6,9). ¹³C NMR δ ppm: 34.3 (3), 35.8 (Br₂CH-7, Br₂CH-8), 128.1 (2',6',2'',6''), 129.2 (3',5',3'',5''), 130.2 (6,9), 131.7 (4',4''), 135.9 (7,8), 136.5 (1',1''), 141.6 (5a,9a), 153.4 (2,4). EIMS: *m/z* (%) 714/716/718/720/722/724 (M⁺, 10),²² 321 (100). Anal. Calcd. for C₂₃H₁₅Br₅N₂ (718.90): C 38.43; H 2.10; N 3.90. Found: C 38.25; H 2.25; N 3.73.

When the bromination was repeated with 7 equivalents of NBS for 4 h the pentabromo-derivative **9** (65% yield) and the hexabromo-derivative **10** (14% yield) were obtained after separation of the crude reaction mixture on a preparative TLC plate.

3-Bromo-8-(dibromomethyl)-2,4-diphenyl-7-(tribromomethyl)-3H-1,5-benzodiazepine (10). Mp 93–95 °C. ¹H NMR δ ppm: 7.04 (1H, s, 3), 7.45–7.57 (6H, m, 3',4',5',3'',4'',5''), 7.84 (1H, s, Br₂CH-8), 7.89–7.99 (4H, m, 2',6',2'',6''), 8.25 (1H, s, 6), 8.50 (1H, s, 9). ¹³C NMR δ ppm: 30.0 (Br₃C-7), 34.3 (3), 37.2 (Br₂CH-8), 128.17 and 128.22 (2',6' and 2'',6''), 129.2 (3',5' and 3'',5''), 127.7 (6), 131.79 and 131.84 (4' and 4''), 136.0 (9), 136.43 and 136.46 (1' and 1''), 137.0 (7), 138.5 (8), 139.7 (5a), 142.6 (9a), 153.5 (4), 153.7 (2). EIMS: *m/z* (%) 792/794/796/798/800/802/804 (M⁺, 8),²² 320 (26). Anal. Calcd. for C₂₃H₁₄Br₆N₂ (797.80): C 34.63; H 1.77; N 3.51. Found: C 34.50; H 1.80; N 3.70.

Bromination of compound **3d** with KBrO₃/NaHSO₃

To a solution of KBrO₃ (0.50 g, 3 mmol) in water (1.5 mL) was added the benzodiazepine **3d** (0.324 g, 1 mmol) in ethyl acetate (2 mL), followed by a solution of NaHSO₃ (0.31 g, 3 mmol) in water (3 mL) over a period of about 15 min, and the mixture was stirred at room temperature for 4 h. The mixture was poured into 20 mL of dichloromethane. After separation of the phases, the aqueous layer was extracted twice with dichloromethane, and the combined organic layer was washed with aqueous Na₂S₂O₄ solution and dried over anhydrous MgSO₄. The solvent was evaporated and the residue was purified by column chromatography to afford in order of elution:

3,3-Dibromo-7,8-dimethyl-2,4-diphenyl-3H-1,5-benzodiazepine (11). Yellow solid, mp 226–228 °C; yield 0.27 g (56%). ¹H NMR δ ppm: 2.43 (6H, s, CH₃-7 and CH₃-8), 7.42–7.50 (6H, m, 3',4',5',3'',4'',5''), 7.67 (2H, s, 6,9), 8.10–8.16 (4H, m, 2',6',2'',6''). ¹³C NMR δ ppm: 19.5

(CH₃-7 and CH₃-8), 29.7 (3), 128.2 (2',6',2'',6''), 129.0 (3',5',3'',5''), 131.2 (4',4''), 131.5 (6,9), 133.2 (7,8), 137.4 (1',1''), 138.5 (5a,9a), 157.3 (2,4). EIMS: *m/z* (%) 480/482/484 (M⁺, 28),²² 401/403 [(M-Br)⁺, 36], 322 (9), 77 (100). Anal. Calcd. for C₂₃H₁₈Br₂N₂ (482.21): C 57.29; H 3.76; N 5.81. Found: C 57.48; H 3.64; N 5.92.

Compound 5 in 23% yield.

Supplementary Information available

References and Notes

1. (a) Schutz, H. In *Benzodiazepines*; Springer: Heildeberg, 1982. (b) Landquist, J. K. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, C. W. Eds.; Pergamon: Oxford, 1984. Vol. 1, pp 166–170.
2. (a) Randall, L. O.; Kappel, B. In *Benzodiazepines*; Garattini, S.; Mussini, E.; Randall, L. O. Eds.; Raven Press: New York, 1973. p. 27 and references cited therein; (b) Di Braccio, M.; Grossi, G.; Roma, G.; Vargiu, L.; Mura, M.; Marongiu, M. E. *Eur. J. Med. Chem.* **2001**, *36*, 935.
3. (a) Haris, R. C.; Straley, J. M. U.S. Patent 1,537,757, 1968; *Chem. Abstr.* **1970**, *73*, 100054w.
4. (a) De Baun, J. R.; Pallos, F. M.; Baker, D. R. U.S. Patent 3,978,227, 1976; *Chem. Abstr.* **1977**, *86*, 5498d.
5. (a) Essaber, M.; Baouid, A.; Hasnaoui, A.; Benharref, A.; Lavergne, J. P. *Synth. Commun.* **1998**, *28*, 4097. (b) El-Sayed, A. M.; Abdel-Ghany, H.; El-Saghier, A. M. M. *Synth. Commun.* **1999**, *29*, 3561. (c) Reddy, K. V. V.; Rao, P. S.; Ashok, D. *Synth. Commun.* **2000**, *30*, 1825. (d) Nabih, K.; Baouid, A.; Hasnaoui, A.; Kenz, A. *Synth. Commun.* **2004**, *34*, 1532.
6. (a) Balakrishna, M. S.; Kaboudin, B. *Tetrahedron Lett.* **2001**, *42*, 1127. (b) Curini, M.; Epifano, F.; Marcotullio, M. C.; Rosati, O. *Tetrahedron Lett.* **2001**, *42*, 3193. (c) Zhong, W.; Zhang, Y.; Chen, X. *Tetrahedron Lett.* **2001**, *42*, 73.
7. (a) Thakuria, H.; Pramanik, A.; Borah, B. M.; Das, G. *Tetrahedron Lett.* **2006**, *47*, 3135. (b) Kumar, R.; Chaudhary, P.; Nimesh, S.; Verma, A. K.; Chandra, R. *Green Chemistry* **2006**, *8*, 519. (c) Du, Y.; Tian, F.; Zhao, W. *Synth. Commun.* **2006**, *36*, 1661.
8. (a) Ried, W.; Stahlhofen, P. *Chem. Ber.* **1957**, *90*, 815. (b) Reid, W.; Torinus, E. *Chem. Ber.* **1959**, *92*, 2902.
9. (a) Despinoy, C.; Lloyd, D.; McNab, H.; Reed, D. *Tetrahedron* **1998**, *54*, 9667. (b) Mansour, O.; Szymonski, B.; Thomasson, F.; Morand, J. M.; Cussac, M. *J. Heterocyclic Chem.* **2001**, *38*, 641. (c) Guzen, K.P.; Cella, R.; Stefani, H. A. *Tetrahedron Lett.* **2006**, *47*, 8133. (d) Polshettiwar, V.; Varka, R.S. *Tetrahedron Lett.*, **2008**, *49*, 397.
10. Ried, W.; Teubner, R. *Liebigs Ann. Chem.* **1978**, 741.

11. Kikuchi, D.; Sakaguchi, S.; Ishii, Y. *J. Org. Chem.* **1998**, *63*, 6023.
12. Ahmad, R.; Zia-ul-Haq, M.; Duddeck, H.; Stefaniak, L.; Sitkowski, J. *Monatsh. Chem.* **1997**, *128*, 633.
13. (a) Ditchfield, R. *Mol. Phys.* **1974**, *27*, 789. (b) Barfiled, M.; Fagerness, P. J. *J. Am. Chem. Soc.* **1997**, *119*, 8699. (c) Manaj, J. M.; Maciewska, D.; Waver, I. *Magn. Reson. Chem.* **2000**, *38*, 482.
14. (a) Yükses, H.; Cakmak, I.; Sadi, S.; Alkan, M.; Baykara, H. *Int. J. Mol. Sci.* **2005**, 219. (b) Wolinski, K.; Hilton, K. J. F.; Pulay, P. *J. Am. Chem. Soc.* **1990**, *112*, 8251.
15. (a) Greenwood, J. R.; Vaccarella, G.; Capper, H. R.; Mewett, K. N.; Allan, R. D.; Johnston, G. A. R. *J. Mol. Struct. (Theochem)* **1996**, *368*, 235. (b) March, J. *Advanced Organic Chemistry. Reactions, Mechanisms, and Structure*, 3rd Edn.; Wiley: New York, 1985; p. 625. (c) Pearson, R. A.; Martin, J. C. *J. Am. Chem. Soc.* **1963**, *85*, 3142.
16. M. Pozarentzi, M.; Tsoleridis, C. A. Stephanidou-Stephanatou, J. Unpublished results.
17. Mopac2000 Ver 1.11. Fujitsu in *Chem3D Ultra 7.0*.
18. (a) Becke, A. D. *J. Chem. Phys.* **1993**, 5648. (b) Lee, C.; Yang, W.; Parr, R. G. *Phys. Rev. B* **1988**, *37*, 785.
19. Frisch, M. J. T.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. *Gaussian03*, revision B.02; Gaussian, Inc.: Pittsburgh PA. 2003.
20. Mannschreck, A.; Rissmann, G.; Vögtle, F.; Wild, D. *Chem. Ber.* **1967**, *100*, 335.
21. Zaika, L. L.; Joullié, M. M. *J. Heterocyclic Chem.* **1966**, *3*, 444.
22. The peak intensity refers to the higher peak of bromine containing ions.